Table 5.
Summary of AEs related to pazopanib (≥30% of patients in any of the three treatment groups) for Cohorts A, B, and C – All-treated population
| Cohort A | Cohort B | Cohort C | |||
|---|---|---|---|---|---|
| AEs | Pazopanib (800 mg QD) + pembrolizumab (2 mg/kg Q3W) (N=10) n (%) |
Pazopanib (600 mg QD) + pembrolizumab (2 mg/kg Q3W) (N=10) n (%) |
Pazopanib + pembrolizumab (N=6) n (%) |
Pembrolizumab (N=4) n (%) |
Pazopanib (N=11) n (%) |
| Any event Diarrhea |
10 (100) 6 (60) |
10 (100) 6 (60) |
6 (100) 5 (83) |
4 (100) 2 (50) |
11 (100) 6 (55) |
| Nausea Vomiting |
6 (60) 5 (50) |
3 (30) 1 (10) |
3 (50) 1 (17) |
0 0 |
6 (55) 6 (55) |
| Fatigue Mucosal inflammation |
4 (40) 4 (40) |
5 (50) 1 (10) |
2 (33) 0 |
1 (25) 0 |
4 (36) 0 |
| Alanine aminotransferase increased Aspartate aminotransferase increased |
7 (70) 7 (70) |
6 (60) 7 (70) |
1 (17) 1 (17) |
3 (75) 3 (75) |
5 (45) 3 (27) |
| Blood alkaline phosphatase increased Pruritus |
3 (30) 3 (30) |
0 1 (10) |
2 (33) 0 |
2 (50) 0 |
2 (18) 0 |
| Rash Hair color changes |
2 (20) 1 (10) |
3 (30) 4 (40) |
0 2 (33) |
0 1 (25) |
0 1 (9) |
| Rash maculopapular Hypertension |
0 3 (30) |
3 (30) 7 (70) |
0 3 (50) |
0 0 |
0 1 (9) |
| Dysgeusia | - | - | 2 (33) | 1 (25) | 4 (36) |
AE, adverse event; Q3W, every 3 weeks; QD, once daily.